Bär & Karrer Ltd. | View firm profile
On 23 October 2020, Kuros Biosciences, a life science company focusing on the development and marketing of orthobiologics, completed a capital increase by way of a rights offering to its shareholders. 50.2% of the shareholders of Kuros Biosciences exercised their subscription rights in the rights offering. The remaining 4,192,530 offered shares were placed in the market and an additional tranche of 1,915,203 shares was sold to Optiverder B.V. The offer price was set at CHF 1.80 per share.
|Bär & Karrer acted as legal adviser to Octavian and Helvetische Bank in this transaction. The team included Thomas U. Reutter, Alexander von Jeinsen and Carlo Hunter (all Capital Markets) as well as Christoph Suter and David Weimann (both Tax).|